HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

John R Su Selected Research

Intracranial Sinus Thrombosis (Sinus Thrombosis)

1/2022Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021.
1/2022Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.
5/2021Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021.
4/2021Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021.
1/2021US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


John R Su Research Topics

Disease

16COVID-19
07/2022 - 04/2021
5Thrombocytopenia (Thrombopenia)
01/2022 - 01/2021
5Intracranial Sinus Thrombosis (Sinus Thrombosis)
01/2022 - 01/2021
5Myocarditis (Carditis)
01/2022 - 07/2021
4Thrombosis (Thrombus)
01/2022 - 04/2021
3Anaphylaxis (Anaphylactic Shock)
03/2021 - 01/2019
3Herpes Zoster
01/2021 - 03/2017
3Mumps
11/2020 - 01/2018
3Measles
11/2020 - 01/2018
2Guillain-Barre Syndrome
01/2022 - 11/2020
2Infections
01/2022 - 01/2018
2Pain (Aches)
12/2021 - 05/2021
2Fatigue
12/2021 - 05/2021
2Human Influenza (Influenza)
01/2021 - 01/2018
2Rubella (German Measles)
11/2020 - 01/2018
2Chickenpox
01/2018 - 03/2017
1COVID-19 related pediatric multisystem inflammatory disease
01/2022
1COVID-19 related adult multisystem inflammatory disease
01/2022
1Ischemic Stroke
01/2022
1Myocardial Infarction
01/2022
1Pulmonary Embolism
01/2022
1Headache (Headaches)
12/2021
1Inflammation (Inflammations)
08/2021
1Pericarditis
07/2021
1Hepatitis B
01/2021
1Hypothyroidism
01/2021
1Smallpox (Variola)
01/2021
1Obesity
01/2021
1Anthrax
01/2021
1Poliomyelitis (Polio)
11/2020
1Intussusception
11/2020
1Stevens-Johnson Syndrome (Lyell's Syndrome)
11/2020
1Erythema Multiforme
11/2020
1Shoulder Injuries
01/2020
1Syncope (Fainting)
12/2019
1Drug Hypersensitivity (Drug Allergy)
01/2019
1Hypersensitivity (Allergy)
01/2019
1Meningococcal Infections
02/2016
1Syphilis
03/2013
1Sepsis (Septicemia)
06/2009

Drug/Important Bio-Agent (IBA)

25VaccinesIBA
07/2022 - 03/2017
11COVID-19 VaccinesIBA
02/2022 - 03/2021
8Messenger RNA (mRNA)IBA
07/2022 - 03/2021
6mRNA VaccinesIBA
07/2022 - 07/2021
4BNT162 VaccineIBA
02/2022 - 07/2021
4Ad26COVS1IBA
02/2022 - 01/2021
32019-nCoV Vaccine mRNA-1273IBA
03/2022 - 01/2022
3Heparin (Liquaemin)FDA LinkGeneric
01/2022 - 06/2009
2Glycoproteins (Glycoprotein)IBA
03/2022 - 07/2021
2AntibodiesIBA
01/2022 - 01/2022
2Chickenpox Vaccine (Vaccine, Varicella)IBA
11/2020 - 01/2018
1NucleosidesIBA
03/2022
1Lipid NanoparticlesIBA
03/2022
1EnzymesIBA
01/2022
1ImmunosorbentsIBA
01/2022
1Proteins (Proteins, Gene)FDA Link
01/2022
1TroponinIBA
01/2022
1Aligeron (AS 2)IBA
12/2021
1Pharmaceutical PreparationsIBA
04/2021
1Oral ContraceptivesIBA
01/2021
1ChAdOx1 nCoV-19IBA
01/2021
1Influenza Vaccines (Influenza Vaccine)FDA Link
11/2020
1Rotavirus VaccinesIBA
11/2020
1Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA
11/2020
1Measles-Mumps-Rubella Vaccine (MMR Vaccine)IBA
11/2020
1Rubella VaccineIBA
11/2020
1Polysaccharides (Glycans)IBA
01/2018
1Inactivated VaccinesIBA
01/2018
1Meningococcal Vaccines (Meningococcal Vaccine)IBA
02/2016
1Conjugate VaccinesIBA
02/2016
1MacrolidesIBA
03/2013
123S Ribosomal RNAIBA
03/2013
1SolutionsIBA
06/2009